邓洪斌课题组聚焦于肿瘤免疫逃逸机制研究及基于新靶点、新机制的小分子肿瘤免疫治疗药物的发现。研究方向主要包括：1、PD-1/PD-L1等肿瘤免疫检查点蛋白分子调控机制的研究，发现药物作用新靶点，研发小分子肿瘤免疫治疗药物。2、肿瘤微环境中肿瘤细胞与免疫细胞相互调节机制研究。3、天然活性药物干预肿瘤微环境中TAM、Treg、MDSC等重塑免疫监控的研究等。近年来，课题组研究工作先后揭示了土贝母苷甲、苦豆碱衍生物SA-49通过溶酶体途径降解PD-L1，激活肿瘤微环境中CD8⁺T细胞发挥抗肿瘤免疫作用；小檗碱通过抑制去泛素化酶CSN5活性降解PD-L1发挥抗肿瘤免疫作用的分子机制。先后主持国家自然科学基金面上项目4项、中国药学会以岭生物医药创新基金等项目，参与“十三五”国家重大专项、中国医学科学院重大协同创新等项目。获授权专利3项，研究成果先后获得2019年和2016年中国药学会科学技术奖二等奖；2012年中国药学会-赛诺菲青年生物药物奖。

课题组近5年课题组代表性论文：

1. Xiaojia Liu^#, Mingxiao Yin^#, Jingwen Dong, Genxiang Mao, Wenjian Min, Zean Kuang, Peng Yang, Lu Liu, Na Zhang, Hongbin Deng^*.  Tubeimoside-1 induces TFEB-dependent lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting mTOR. Acta Pharmaceutica Sinica B, 2021, in press. https://doi.org/10.1016/j.apsb.2021.03.039

2. Yang Liu^#, Xiaojia Liu^#, Na Zhang^#, Mingxiao Yin, Jingwen Dong, Qingxuan Zeng, Genxiang Mao, Danqing Song, Lu Liu^*, Hongbin Deng^*.  Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5.  Acta Pharmaceutica Sinica B, 2020, 10 (12): 2299-2312.

3. Qingxuan Zeng^#, Hongbin Deng^#, Yinghong Li^#, Tianyun Fan, Yang Liu, Sheng Tang, Wei Wei, Xiaojia Liu, Xixi Guo, Jiandong Jiang, Yanxiang Wang^* Danqing Song^*. Berberine Directly Targets the NEK7 Protein to Block the NEK7- NLRP3 Interaction and Exert Anti-inflammatory Activity. Journal of Medicinal Chemistry, 2021, 64(1): 768-781.

4. Na Zhang^#, Yueying Dou^#, Lu Liu, Xin Zhang, Xiaojia Liu, Qingxuan Zeng, Yang Liu, Mingxiao Yin, Xiujun Liu, Hongbin Deng^* and Danqing Song^*. SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1. EBioMedicine. 2019, 40:151-162.

5. Xiaojia Liu^#, Na Zhang^#, Yang Liu, Lu Liu, Qingxuan Zeng, Mingxiao Yin, Yanxiang Wang, Danqing Song*, and Hongbin Deng*. MPB, a novel Berberine derivative, enhances lysosomal and bactericidal properties via TGF-β-activated kinase 1-dependent activation of the transcription factor EB. The FASEB Journal, 2019, 33(1):1468-1481.

6. Lu Liu^#, Yang Liu^#, Xiaojia Liu, Na Zhang, Genxiang Mao, Qingxuan Zeng, Mingxiao Yin, Danqing Song, Hongbin Deng*. Resibufogenin suppresses TAK1-mediated NF-κB activity via protein kinase C-dependent inhibition of glycogen synthase kinase 3. Cancer Science, 2018, 109: 3611-3622.

7. Xin Zhang^#, Qiang Liu^#, Na Zhang, Qian-Qian Li, Zhan-Dong Liu, Ying-Hong Li, Li-Mei Gao, You-Chun Wang, Hong-Bin Deng*, Dan-Qing Song*. Discovery and evolution of aloperine derivatives as novel anti-filovirus agents through targeting entry stage. European Journal of Medicinal Chemistry, 2018, 149: 45-55.

8. Na Zhang^#, Xiaojia Liu^#, Lu Liu, Zhesong Deng, Qingxuan Zeng, Weiqiang Pang, Yang Liu, Danqing Song^*, Hongbin Deng^*. Glycogen synthase kinase-3β inhibition promotes lysosome-dependent degradation of c-FLIP_L in hepatocellular carcinoma. Cell Death & Disease, 2018, 9(2):230.

9. Yan-xiang Wang^#, Weiqiang Pang^#, Qing-xuan Zeng, Zhe-song Deng, Tian-yun Fan, Jian-dong Jiang, Hongbin Deng*, Dan-qing Song*. Synthesis and biological evaluation of new berberine derivatives as cancer immunotherapy agents through targeting IDO1. European Journal of Medicinal Chemistry, 2018, 143:1858-1868.

10. Lu Liu , Na Zhang , Yueying Dou , Genxiang Mao , Chongwen Bi , Weiqiang Pang , Xiaojia Liu , Danqing Song^*, Hongbin Deng^*. Lysosomal dysfunction and autophagy blockade contribute to IMB-6G-induced apoptosis in pancreatic cancer cells. Scientific Reports, 2017, 7:41862.

课题组申请和获得的发明专利：

1. 苦豆碱衍生物在制备治疗肿瘤的药物中的应用

授权专利号：CN106822129B，授权公告日：2019.9.3

发明人：宋丹青，邓洪斌，张欣，张靖溥，窦玥莹，唐胜，汪燕翔，李迎红，张娜

2. 抗肿瘤药物和用途

授权专利号：CN111675747B，授权公告日：2021.4.27

发明人：邓洪斌，刘晓嘉，冯艳春，张娜，宋丹青，殷明晓，董靖雯，曾庆轩

3. 川楝素作为吲哚胺2,3-双加氧酶1 抑制剂的用途

申请号：202010764162.8， 申请日期：2020.7.30

发明人：邓洪斌，刘晓嘉，冯艳春，殷明晓，董靖雯，庞伟强，况泽安